InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Quince Therapeutics, Inc.

QNCX Clue Score7
United States Fiscal year ends December CIK 0001662774
$31.73 +8.07% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $31.73 −59.64% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 9 May 2019. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2018Operating income−12.1Net income−12.5Fiscal year 2019Operating income−39.2Net income−37.0Fiscal year 2020Operating income−78.9Net income−76.8Fiscal year 2021Operating income−90.3Net income−89.9EPS, diluted−3.03Fiscal year 2022Operating income−52.0Net income−51.7EPS, diluted−1.54Fiscal year 2023Operating income−34.6Net income−31.4EPS, diluted−0.84Fiscal year 2024Operating income−57.3Net income−56.8EPS, diluted−1.31Fiscal year 2025Operating income−58.1Net income−84.0EPS, diluted−1.68
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −12.1 −39.2 −78.9 −90.3 −52.0 −34.6 −57.3 −58.1
Net income −12.5 −37.0 −76.8 −89.9 −51.7 −31.4 −56.8 −84.0
Growth
EPS, diluted n/a n/a n/a −3.03 −1.54 −0.84 −1.31 −1.68
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2018Operating cash flow−11.7Capital expenditure−0.2Free cash flow−11.9Fiscal year 2019Operating cash flow−33.3Capital expenditure−0.1Free cash flow−33.3Fiscal year 2020Operating cash flow−50.8Capital expenditure−0.1Free cash flow−50.9Fiscal year 2021Operating cash flow−62.9Capital expenditure−0.2Free cash flow−63.1Fiscal year 2022Operating cash flow−44.0Capital expenditure−0.1Free cash flow−44.2Fiscal year 2023Operating cash flow−18.3Capital expenditure−0.2Free cash flow−18.5Fiscal year 2024Operating cash flow−31.9Capital expenditure−0.3Free cash flow−32.2Fiscal year 2025Operating cash flow−41.4Capital expenditure−0.4Free cash flow−41.8
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −11.7 −33.3 −50.8 −62.9 −44.0 −18.3 −31.9 −41.4
Capital expenditure −0.2 −0.1 −0.1 −0.2 −0.1 −0.2 −0.3 −0.4
Free cash flow −11.9 −33.3 −50.9 −63.1 −44.2 −18.5 −32.2 −41.8
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2018Cash24.9Shareholders’ equity−32.6Fiscal year 2019Cash51.2Shareholders’ equity115.5Fiscal year 2020Cash66.8Shareholders’ equity172.3Fiscal year 2021Cash29.5Shareholders’ equity118.6Fiscal year 2022Cash40.6Total debt0.0Net cash (debt)40.6Shareholders’ equity100.6Debt to equity0.00Fiscal year 2023Cash20.8Total debt13.4Net cash (debt)7.3Shareholders’ equity85.1Debt to equity0.16Fiscal year 2024Cash6.2Total debt14.3Net cash (debt)−8.1Shareholders’ equity30.1Debt to equity0.48Fiscal year 2025Cash5.8Total debt18.0Net cash (debt)−12.2Shareholders’ equity−35.7
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 24.9 51.2 66.8 29.5 40.6 20.8 6.2 5.8
Total debt n/a n/a n/a n/a 0.0 13.4 14.3 18.0
Net cash (debt) n/a n/a n/a n/a 40.6 7.3 −8.1 −12.2
Shareholders’ equity −32.6 115.5 172.3 118.6 100.6 85.1 30.1 −35.7
Debt to equity n/a n/a n/a n/a 0.00 0.16 0.48 n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −32.0% −44.6% −75.8% −51.4% −36.9% −188.5% n/a
−17.1% −29.7% −40.6% −67.5% −49.7% −18.7% −49.6% −89.8%
Balance and payout
n/a n/a n/a n/a 0.00 0.16 0.48 n/a
2.0% 7.1% 9.1% 11.0% 3.2% 49.3% 73.7% 138.2%